From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Combination of
Clinical data
Trade namesPyramax[2]
SynonymsArtesunate/pyronaridine tetraphosphate[2]
Routes of
By mouth[1]
ATC code

Artesunate/pyronaridine, sold under the brand name Pyramax, is a fixed dose combination medication for the treatment of malaria.[3][2] It can be used for malaria of both the P. falciparum and P. vivax types.[2] It combines artesunate and pyronaridine.[3] It is taken by mouth.[1]

The combination is generally well tolerated.[2] Side effects may include headache, vomiting, or cough.[2] Use in those with severe liver disease or kidney disease is not recommended.[1] Use is not generally recommended in early pregnancy.[1] However, there are no other options and if treatment may save the mother's life it may be used.[1] The two components work by different mechanisms.[1]

It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] In 2010 the wholesale cost of a course of treatment in the developing world was between 0.55 and 2.18 USD.[2]

Medical uses[edit]

Artesunate/pyronaridine is used for malaria of both the P. falciparum and P. vivax types.[2] It is not recommended for severe disease.[1]

A 2014 review found that the combination compared well to artemether/lumefantrine.[4] Benefits also appear similar to mefloquine together with artesunate.[4] It is not recommended for the prevention of malaria.[1]


  1. ^ a b c d e f g h "Pyramax 180 mg/60 mg Film-coated tablet" (PDF). EMA. Retrieved 13 December 2017.
  2. ^ a b c d e f g h "Application for inclusion in the WHO Model List of essential medicines" (PDF). WHO. Nov 2010. Retrieved 29 June 2017.
  3. ^ a b c "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.
  4. ^ a b Bukirwa, H; Unnikrishnan, B; Kramer, CV; Sinclair, D; Nair, S; Tharyan, P (4 March 2014). "Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria". The Cochrane Database of Systematic Reviews (3): CD006404. doi:10.1002/14651858.CD006404.pub2. PMC 4448218. PMID 24596021.